|Articles|January 1, 1998

A Managed Care Appraisal of Atypical Agents in the Treatment of Psychoses
Volume 4
Issue 1 Suppl

Introduction - The Routine Use of Atypical Antipsychotics

Download PDF: Introduction - The Routine Use of Atypical Antipsychotics

Articles in this issue

over 28 years ago

Article

Common Treatment Goals: Switching Antipsychotics

over 28 years ago

Article

Antipsychotics : Present and Future

over 28 years ago

Article

Atypical Antipsychotics in the Managed Care Era

over 28 years ago

Article

CME Quiz

over 28 years ago

Article

Selected Abstracts

over 28 years ago

Article

Bibliography

over 28 years ago

Article

Participating Faculty

over 28 years ago

Article

Atypical Antipsychotics and Formulary Decisions

over 28 years ago

Article

Chronic Ambulatory Outpatients and Four-Vector Management

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

State Medicaid Budgetary Implications of New Cancers

ByAmanda C. Chen, PhD,Anuraag R. Kansal, PhD,David C. Grabowski, PhD

July 2nd 2026

Blood Pressure Control Among Adherent vs Nonadherent Medicare Patients With Hypertension

ByKaitlyn T. Haas, PharmD,Joseph J. Saseen, PharmD, BCPS, BCACP,Oliver Titus, MS,Nathan Lamberton, PharmD, BCACP,Lisa M. Schilling, MD, MSPH,Keri N. Hogan, PharmD, BCACP,Alison Marks, BA,Sarah J. Billups, PharmD, BCPS

July 1st 2026

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Introduction - The Routine Use of Atypical Antipsychotics

Articles in this issue

Related Content

State Medicaid Budgetary Implications of New Cancers

Blood Pressure Control Among Adherent vs Nonadherent Medicare Patients With Hypertension

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Trending on AJMC

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

Real-World Data Show MASH Progresses Faster Than Trials Suggest

Sarcoma's Rarity Limits Trials and Biomarker-Driven Treatment Options: Alexander Spira, MD, PhD, FACP, FASCO

Early Treatment Succeeds in CRC With Next Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo

SYNC-T: Immunotherapy Platform Brings 4-Part Attack in Prostate Cancer, With More Trials Planned

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Introduction - The Routine Use of Atypical Antipsychotics

Articles in this issue

Related Content

State Medicaid Budgetary Implications of New Cancers

Blood Pressure Control Among Adherent vs Nonadherent Medicare Patients With Hypertension

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Trending on AJMC

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

Real-World Data Show MASH Progresses Faster Than Trials Suggest

Sarcoma's Rarity Limits Trials and Biomarker-Driven Treatment Options: Alexander Spira, MD, PhD, FACP, FASCO

Early Treatment Succeeds in CRC With Next Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo

SYNC-T: Immunotherapy Platform Brings 4-Part Attack in Prostate Cancer, With More Trials Planned